I read few more times about patients and trials , I think you and Zuess , you both right , they talking about all our trials..

I was just surprise with this statement , because when once I did a study for Hoffmann La Roche ,
They had few meetings with me before they even send IND to FDA , what type of patients I will need , and before they filed I had my list of patients I spoke with , who were great candidates for this study.
This is why I remembered it on the spot...